[{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Phase II\/ Phase III","graph3":"Incyte Corporation","amount2":2,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Oncology","amount2New":2,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"9","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Itacitinib","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Retifanlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0.90000000000000002,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.90000000000000002,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Pemigatinib","moa":"FGFR","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Merus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"MCLA-145","moa":"CD137","graph1":"Oncology","graph2":"Phase I","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"intravenous infusion","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Retifanlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Cellenkos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Oncology","graph2":"Undisclosed","graph3":"Incyte Corporation","amount2":0.28999999999999998,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0.28999999999999998,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"1","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Calithera Biosciences","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"INCB001158","moa":"Aarginase","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"ONCOtherapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Oncology","graph2":"Phase I","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"6","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Retifanlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0.01,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous infusion","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ MorphoSys"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ MorphoSys"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"InnoCare Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0.12,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"","sponsorNew":"Incyte Corporation \/ InnoCare Pharma","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ InnoCare Pharma"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Incyte Corporation \/ MorphoSys","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ MorphoSys"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Nimble Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0.59999999999999998,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.59999999999999998,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Large molecule","year":"2021","type":"Agreement","leadProduct":"Tafasitamab","moa":"CD19","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","graph1":"Immunology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2021","type":"Collaboration","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0.14999999999999999,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0.14999999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Merus","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Incyte Corporation \/ Merus","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Merus"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Maruho","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Agreement","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Maruho","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Maruho"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Capmatinib Hydrochloride","moa":"c-Met","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"SWITZERLAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Immunology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"PI3K delta","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Eli Lilly","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Baricitinib","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Specialised Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Pemigatinib","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Specialised Therapeutics","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Specialised Therapeutics"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"BriaCell Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"SV-BR-1-GM","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Mirati Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"INCB99280","moa":"PD-L1","graph1":"Oncology","graph2":"Preclinical","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Mirati Therapeutics","highestDevelopmentStatusID":"4","companyTruncated":"Incyte Corporation \/ Mirati Therapeutics"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"INCAGN01876","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"CMS","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Ruxolitinib Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ CMS","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ CMS"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Villaris Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Large molecule","year":"2022","type":"Acquisition","leadProduct":"Auremolimab","moa":"CD122","graph1":"Dermatology","graph2":"IND Enabling","graph3":"Incyte Corporation","amount2":1.4299999999999999,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Dermatology","amount2New":1.4299999999999999,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"5","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Povorcitinib","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Parsaclisib","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Retifanlimab-dlwr","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0.90000000000000002,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.90000000000000002,"dosageForm":"Injectable\/Injection","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"Retifanlimab-dlwr","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Pemigatinib","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"BioTheryX","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Incyte Corporation","amount2":0.35999999999999999,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.35999999999999999,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Replimune","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Vusolimogene Oderparepvec","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Incyte Corporation","amount2":0.19,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"2","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"AbCellera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Large molecule","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MorphoSys","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Tafasitamab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0.029999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Axatilimab","moa":"","graph1":"Immunology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Povorcitinib","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Ruxolitinib Phosphate","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"China Medical System Holdings Limited","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Povorcitinib","moa":"","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Incyte Corporation \/ China Medical System Holdings Limited","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ China Medical System Holdings Limited"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Escient Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"EP262","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.75,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Escient Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"EP262","moa":"","graph1":"Dermatology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0.75,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0.75,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"MacroGenics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0.91000000000000003,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.91000000000000003,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Axatilimab","moa":"","graph1":"Immunology","graph2":"Approved","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Tafasitamab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"INCB123667","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"INCB000262","moa":"","graph1":"Immunology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Retifanlimab","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Incyte Corporation \/ Not Applicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Syndax Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Axatilimab","moa":"CSF-1R","graph1":"Immunology","graph2":"Approved FDF","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Incyte Corporation \/ Syndax Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Incyte Corporation \/ Syndax Pharmaceuticals"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Genesis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Technology","graph2":"Discovery Platform","graph3":"Incyte Corporation","amount2":0.33000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":0.33000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Incyte Corporation \/ Incyte Corporation"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Ponatinib","moa":"ABL1","graph1":"Oncology","graph2":"Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Ruxolitinib Phosphate","moa":"JAK1\/JAK2","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Cream","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"},{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Povorcitinib","moa":"JAK1","graph1":"Dermatology","graph2":"Phase III","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"Incyte Corporation \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Incyte Corporation \/ Inapplicable"}]